Podcasts about breast cancer research program

Ellacor is a new technology called fractional micro-coring and is a non-surgical solution for mid-to-lower face wrinkles and excess skin. Dr. Michael Cameron, a board-certified dermatologist with a private practice on the upper west side of Manhattan and an assistant clinical professor at Mount Sinai Health System, has one of the few devices commercially available in New York City. Ellacor is an option for patient who want to avoid surgery but address jowels or your heavy lower face. He talks with Michelle about this and how it compares to other cosmetic options.It's hard to believe but back-to-school season is already upon us and now is the perfect time to equip your kids with everything they need to take on the new school year. Justine Santaniello, Lifestyle & Parenting Expert, helps alleviate the stress that comes with back-to-school prep and share ways that parents can set their kids up for success at the start of the new school year. Justine will also provide tips on preparing fun lunch and snack ideas, time saving hacks, how to stay organized, and more!Diggerland USA is the only construction theme & water park in the US. Families can drive, ride & operate real machines in a safe, clean and fun gated theme park. During the summer months, guests can splash, soak and slide at The Water Main water park, nestled inside the theme park and included in admission. Children over 36” tall can enjoy most rides in the park with an accompanying adult. Along with over 40+ rides and attractions, the park also offers a full-service arcade, cafes, gift shop with unique merchandise, eating pavilions, cabana rentals and more. The park was started in 2014 by brothers, Ilya and Yan Girlya, who had previously been in the construction industry and wanted to find a way for families to enjoy construction machines and increase awareness in the general field. Michelle talks with Ilya about how unique this park is and what a blast it was for her family!Dr. Mothaffar F. Rimawi is a Professor of Medicine, co-Leader of the Breast Cancer Research Program, and Executive Medical Director of the Dan L Duncan Comprehensive Cancer Center (DLDCCC) at Baylor College of Medicine. Metastatic breast cancer (mBC) is the most serious form of the disease and occurs when the cancer has spread beyond the breast to other parts of the body, such as the brain, bones, or liver.1 mBC has no cure and takes a life in the United States approximately every 12 minutes, creating an urgent need for treatment proven to extend life while maintaining quality of life. Despite remaining gaps, there have been important advancements in treatment for patients with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) mBC. For example, KISQALI® (ribociclib), a prescription medicine indicated for HR+/HER2- mBC in combination with endocrine therapy (ET), has consistently demonstrated across three phase III clinical trials a significant benefit in overall survival (OS) – the length of time that patients diagnosed with mBC continue to be alive – while preserving or improving quality of life.

Marking a significant advance in infant safety, the U.S. Food and Drug Administration (FDA) has given De Novo approval to Happiest Baby's SNOO Smart Sleeper. This is the first time the FDA has given De Novo approval to a product designed to keep sleeping babies safely positioned on the back. Babies who are positioned to sleep on the back are at a lower risk of SIDS. Amy Schumer, Tia Mowry, Ashton Kutcher, Gigi Hadid, Serena Williams, and Kate Hudson are just a few who have used and praised the SNOO Smart Sleeper. Michelle speaks with Dr. Harvey Karp about how to calm your baby and the great benefits of the SNOO.Due to severe food allergies, Hero Bread Founder Cole Glass has an extremely limited diet. He can't eat raw fruits, vegetables or nuts, which means he's limited to protein, fat and carbs. Glass was worried about the health impacts of all the carbohydrate-dense foods he was eating and started searching for a low net carb bread. The problem was, most of the alternative flour products were made from foods he couldn't eat. So, he decided to bake. Without a culinary background, it took two years of experimentation and 73,000 muffins, but practice paid off and he found the perfect recipe. His bread has zero grams of sugar, 12 grams of protein and only 1 net carb per serving.That journey led him to big-name investors, expansion into quick-service and his latest Series B fundraise (bringing total funding to date to $47.5 million). Hero Bread is also expanding to 2,300 grocery retail stores nationwide. Milan Kordestani, an expert for “Gen Next” (Millennials, Gen Z, and Gen Alpha). He is an entrepreneur, writer, and founder of several companies, who is redefining the meaning of success in business. With a focus on building sustainable businesses that drive positive social change at scale, Milan is a three-time founder who wants to encourage solutions beyond his companies through storytelling and narration of civil discourse. Milan is also the author of “I'm Just Saying: A Guide to Maintaining Civil Discourse in an Increasingly Divided World,” (April, 2023 HCI) a straightforward look at the history and art of maintaining courteous communication in an increasingly divided world. In this book, he uses contemporary case studies and personal experience to teach readers how to have constructive conversations by engaging in civil discourse, and provides practical advice and strategies for respect in a divided world.Dr. Mothaffar F. Rimawi is a Professor of Medicine, co-Leader of the Breast Cancer Research Program, and Executive Medical Director of the Dan L Duncan Comprehensive Cancer Center (DLDCCC) at Baylor College of Medicine. Metastatic breast cancer (mBC) is the most serious form of the disease and occurs when the cancer has spread beyond the breast to other parts of the body, such as the brain, bones, or liver.1 mBC has no cure and takes a life in the United States approximately every 12 minutes, creating an urgent need for treatment proven to extend life while maintaining quality of life. Despite remaining gaps, there have been important advancements in treatment for patients with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) mBC. For example, KISQALI® (ribociclib), a prescription medicine indicated for HR+/HER2- mBC in combination with endocrine therapy (ET), has consistently demonstrated across three phase III clinical trials a significant benefit in overall survival (OS) – the length of time that patients diagnosed with mBC continue to be alive – while preserving or improving quality of life.

On this episode, PrecisCa speaks with Dr. Joyce O'Shaughnessy, a medical oncologist and the Director of Breast Cancer Research Program at Baylor University Medical Center in Dallas, Texas.    Dr. O'Shaughnessy sits down with us to answer the following questions: Which breast cancer patients are eligible for preoperative pembrolizumab in the curative setting based on the KEYNOTE-522 trial? What about adjuvant pembrolizumab? How is trastuzumab deruxtecan optimally utilized for HER2+ metastatic breast cancer? Which CDK 4/6 inhibitor is recommended for treatment of HR+ HER2- metastatic breast cancer based on available survival data? Can you discuss the data from the MonarchE Trial that led to FDA approval of abemaciclib in October 2021? Joyce A. O'Shaughnessy, M.D. focuses on breast cancer prevention and treatment. She is Co-Chair of Breast Cancer Research and Chair of Breast Cancer Prevention Research at Baylor-Sammons Cancer Center and for The US Oncology Network and is a member of the Scientific Advisory Board for US Oncology Research Network. In 2009 D Magazine elected Dr. O'Shaughnessy as one of the best hematology oncologists in Dallas, Texas.    Dr. O'Shaughnessy received her M.D. from Yale University Medical School. Her internship and residency in internal medicine were completed at Massachusetts General Hospital in 1985. She concluded a fellowship in medical oncology at the National Cancer Institute in 1987 and was a Senior Investigator there until 1995. Dr. O'Shaughnessy is a member of American Association for Cancer Research; American Society of Clinical Oncology; American Medical Women's Association; American Medical Association; American College of Physicians; and Women in Cancer Research. Dr. O'Shaughnessy is an Associate Editor, Clinical Breast Cancer Journal; founder, The School of Breast Oncology. Visit www.precisca.com for more resources, content, and access to our entire catalogue of educational content. 

According to The American Cancer Society, Metastatic breast cancer (mBC) is the most serious form of the disease and takes a life in the United States approximately every 12 minutes creating an urgent need for treatment proven to extend life while preserving quality of life. My guests, Dr. Denise A. Yardley, a MONALEESA-2 Investigator, Breast Cancer Research Program, Sarah Cannon Research Institute and Shirley A. Mertz, President, Metastatic Breast Cancer Network, join me with the updated results of a targeted treatment  from the Monaleesa-2 trial.

According to The American Cancer Society, Metastatic breast cancer (mBC) is the most serious form of the disease and takes a life in the United States approximately every 12 minutes creating an urgent need for treatment proven to extend life while preserving quality of life. My guests, Dr. Denise A. Yardley, a MONALEESA-2 Investigator, Breast Cancer Research Program, Sarah Cannon Research Institute and Shirley A. Mertz, President, Metastatic Breast Cancer Network, join me with the updated results of a targeted treatment  from the Monaleesa-2 trial.

In this episode, Christine Hodgdon and Julia Maués, co-founders of Guiding Researchers and Advocates to Scientific Partnerships, and Stephanie L. Graff, MD, FACP, discuss the organization's mission and the importance of patient advocacy. Intro :01 Welcome to another exciting episode of Oncology Overdrive :13 Guest introduction :23 About GRASP :28 About Maués :36 About Hodgdon 1:07 About Graff 1:40 Can you tell us a little bit about GRASP? 2:21 Julia, what was your journey to get into this process? 5:47 Graff how are you involved with GRASP? 9:26 How was something like GRASP not already implemented? 13:30 Julia and Christine, did you have any scientific background before you started doing this? 16:48 Why is advocacy so important? 19:12 Have you guys had any negative responses with this whole patient advocate title? 24:58 Sometimes women's symptoms and concerns are written off or ignored … Julia is that something you've personally experienced or seen? 29:59 Hodgdon's one pearl 39:08 Maués' one pearl 39:56 Graff's one pearl 40:59 How to contact Graff 42:23 How to contact Maués 42:38 How to contact Hodgdon 42:57 Thank you so much for your time 43:27 We'd love to hear from you! Send your comments/questions to oncologyoverdrive@healio.com. Follow us on Twitter @HemOncToday, @ShikhaJainMD, @christeeny513, @itsnot_pink, @DrSGraff and @GRASPtweets. Stephanie L. Graff, MD, FACP, joined Lifespan Cancer Institute at Brown University in Providence, Rhode Island as the director of breast oncology in the summer of 2021. Prior to joining the team at Lifespan/Brown, she was director of both the breast program and clinical research at the Sarah Cannon Cancer Institute at HCA Midwest and associate director of the Breast Cancer Research Program at Sarah Cannon Research Institute and national breast lead for the Sarah Cannon Cancer Network's clinical programs. In addition, Graff serves as a medical advisor to the Dr. Susan Love Foundation for Breast Cancer Research. Christine Hodgdon, is a co-founder of GRASP. Julia Maués is a co-founder of GRASP. Disclosures: Graff, Hodgdon and Maués report no relevant financial disclosures. Jain reports she is a paid freelance writer for Lippincott.

In this episode, Stephanie Graff, MD, FACP, shares the details of her new role at Lifespan Cancer Institute at Brown University, how social media has impacted her career and the importance of fostering relationships with patients. Intro :13 About Graff :18 The interview 2:09 How did you end up in medicine and oncology? 2:32 How did this opportunity come about, and how did you make the decision? 6:47 How do you advise folks regarding career transitions or first jobs out of training? 16:45 How do you think social media has impacted your career? What do you say to the naysayers? 22:14 How have you utilized ASCO throughout your career? 32:24 What do you hope to accomplish at Brown? 37:14 Graff's take-home message 41:13 How to find Graff 42:18 Stephanie Graff, MD, FACP, joined Lifespan Cancer Institute at Brown University in Providence, Rhode Island as the director of breast oncology in the summer of 2021. Prior to joining the team at Lifespan/Brown, she was director of both the breast program and clinical research at the Sarah Cannon Cancer Institute at HCA Midwest and associate director of the Breast Cancer Research Program at Sarah Cannon Research Institute and national breast lead for the Sarah Cannon Cancer Network's clinical programs. In addition, Graff serves as a medical advisor to the Dr. Susan Love Foundation for Breast Cancer Research. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow us on Twitter @HemOncToday @ShikhaJainMD. Dr. Graff can be found on Twitter @DrSGraff.  Disclosures: Graff reports no relevant financial disclosures. Jain reports she is a paid freelance writer for Lippincott.

Black women who are diagnosed with breast cancer are 71% more likely to die. This week.s guest, Jamil Rivers, has made it her life's work to explore this disparity and find solutions. Jamil talks with Cal about her organization, The Chrysalis Initiative, their programs, and what is really driving those outcome disparities. Jamil also talks about what happens when you address the biases that drive disparities. ********** Find out more and support The Chrysalis Initiative: https://thechrysalisinitiative.org ********** Support your favorite podcast on Patreon: patreon.com/interdisciplinary ********** About Our Guest: Jamil Rivers was diagnosed with de novo metastatic breast cancer at age 39. Determined to do everything to be here for her children, husband, and family, she researched vigorously how to best prepare for breast cancer and treatment. Jamil started treatment with chemotherapy and supported her health by improving her nutrition with food and supplements and integrative therapies. She is now doing well and on hormonal therapy. Jamil continues to work full-time and live an active life. She believes the research she did to prepare herself for her cancer has been critical in her recovery and overall wellness. She became an advocate to use her voice and experiences to help advance legislative policy, medical research, and to promote care that better meets the needs of individuals impacted by breast cancer, particularly Black and metastatic patients. Jamil is the board president of METAvivor, and on the Board of Directors of Healwell and Living Beyond Breast Cancer. She is a policy and science advocate and metastatic and African-American health equity advisory committee member with Susan G. Komen. She is a member and patient advisor of the Metastatic Breast Cancer Alliance. She is a proposal reviewer for the Breast Cancer Research Program with the Department of Defense and a Project LEAD graduate. She is a Steering Committee member of the Clinical Trials Transformation Initiative. Jamil also launched The Chrysalis Initiative which provides one-on-coaching and patient navigation support to women with breast cancer, engages in outreach and education for Black women to assess their breast cancer risk and provides training and solutions for providers to ensure equitable care. Through Jamil's work, she has participated in countless community health events, facilitated the design and funding of two metastatic clinical trials, met with leadership within the Pennsylvania governor's office and congressional leaders in Washington, D.C., testified to the Food and Drug Administration, and connected numerous women to resources for screenings, treatment, and support. Jamil and her husband, Rick, have three children and reside in Drexel Hill,Pennsylvania.

Bárbara Segarra-Vázquez, D.H.Sc., has been a faculty member at the University of Puerto Rico for more than 30 years, is the Dean of the School of Health Professions, and the Principal Investigators of a R25 training program for young investigators funded by NIMHD. Dr. Segarra-Vázquez is a two time breast cancer survivor and became an advocate after her first diagnosis. She became a volunteer for Komen Puerto Rico and was Board President for four years. Under her leadership the PR Affiliate received the Komen Promise Award. She has also traveled to Komen Global Initiative to meet with different groups that provided services to breast cancer patients and participated in a public activity of breast. Dr. Segarra-Vazquez is very active as a research advocate and one of her main focus is to increase diversity in clinical trials. She has served several times as a consumer reviewer for the Breast Cancer Research Program of the DoD. She is the Vice-Chair of the Susan G. Komen Advocates in Science Steering Committee, and is a member of SWOG Cancer Network Patient Advocates Committee and the Cancer Care Delivery Committee. She was a member of the Puerto Rico Cancer Control Coalition for ten years. She is the co-founder and co-investigator of HIDEAS (Hispanics Increasing Diversity to Enhance Advocacy in Science).

 Jamil Rivers (@JamilKali) returns to continue our conversation about patient advocacy and how to support and find resources for cancer patients!Jamil Rivers was diagnosed with metastatic breast cancer de novo at age 39. Determined to fight and be here for her children, husband and family, she researched vigorously to learn how to best prepare for her battle to survive. With chemotherapy in conjunction with improving her nutrition with food and supplements and incorporating integrative therapies, she is doing well and now on endocrine therapy. She continues to work full-time as a nonprofit CFO and live an active life. She became an advocate to use her voice and experiences to help advance legislative policy, medical research and customize support to better meet the needs of individuals impacted by breast cancer, particularly metastatic and African-American patients. Jamil is a Young Advocate Alum and Board Member of Living Beyond Breast Cancer. She is the Board President of METAvivor. She is a policy, science and health equity advocate and metastatic advisory committee member with Susan G. Komen. She is a member and patient advisor of the Metastatic Breast Cancer Alliance. She is a proposal reviewer for the Breast Cancer Research Program with the Department of Defense and a Project LEAD graduate. She also launched The Chrysalis Initiative which provides mentoring and resource navigation to women with breast cancer and engages in outreach and education for African-American women to assess their breast cancer risk. Through Jamil’s work, she has participated in countless community health events, facilitated the design and funding of two metastatic clinical trials, met with leadership within the PA governor’s office and congressional leaders in D.C., testified to the FDA, and connected numerous women to resources for screenings, treatment and support. Jamil has been featured in People Magazine, the Philadelphia Inquirer, the Philadelphia Tribune, Wildfire Magazine, national campaigns for Anthropologie, Novartis, Pfizer and Cancer and Careers and on CBS News and Good Morning America. New Episodes every Tuesday! Rate and Subscribe so you don't miss a beat! Also, join us for our monthly live podcasts on Facebook and Youtube!Join the Conversation! Follow us on social media!3 Black Docsfacebook.com/3blackdocstwitter.com/3blackdocsinstagram.com/3blackdocsYouTube.com/3blackdocsDr. Karen Winkfieldfacebook.com/drkarenwinkfieldtwitter.com/drwinkfieldinstagram.com/drwinkfieldDr. Zanetta Lamarfacebook.com/drzanettainstagram.com/drzanetta

This week we are joined by the incredible Jamil Rivers (@JamilKali) who shares her story of surviving metastatic breast cancer and becoming an advocate for other patients. Tune in for Part II next week! Jamil Rivers was diagnosed with metastatic breast cancer de novo at age 39. Determined to fight and be here for her children, husband and family, she researched vigorously to learn how to best prepare for her battle to survive. With chemotherapy in conjunction with improving her nutrition with food and supplements and incorporating integrative therapies, she is doing well and now on endocrine therapy. She continues to work full-time as a nonprofit CFO and live an active life. She became an advocate to use her voice and experiences to help advance legislative policy, medical research and customize support to better meet the needs of individuals impacted by breast cancer, particularly metastatic and African-American patients. Jamil is a Young Advocate Alum and Board Member of Living Beyond Breast Cancer. She is the Board President of METAvivor. She is a policy, science and health equity advocate and metastatic advisory committee member with Susan G. Komen. She is a member and patient advisor of the Metastatic Breast Cancer Alliance. She is a proposal reviewer for the Breast Cancer Research Program with the Department of Defense and a Project LEAD graduate. She also launched The Chrysalis Initiative which provides mentoring and resource navigation to women with breast cancer and engages in outreach and education for African-American women to assess their breast cancer risk. Through Jamil’s work, she has participated in countless community health events, facilitated the design and funding of two metastatic clinical trials, met with leadership within the PA governor’s office and congressional leaders in D.C., testified to the FDA, and connected numerous women to resources for screenings, treatment and support. Jamil has been featured in People Magazine, the Philadelphia Inquirer, the Philadelphia Tribune, Wildfire Magazine, national campaigns for Anthropologie, Novartis, Pfizer and Cancer and Careers and on CBS News and Good Morning America. New Episodes every Tuesday! Rate and Subscribe so you don't miss a beat! Also, join us for our monthly live podcasts on Facebook and Youtube!Join the Conversation! Follow us on social media!3 Black Docsfacebook.com/3blackdocstwitter.com/3blackdocsinstagram.com/3blackdocsYouTube.com/3blackdocsDr. Karen Winkfieldfacebook.com/drkarenwinkfieldtwitter.com/drwinkfieldinstagram.com/drwinkfieldDr. Zanetta Lamarfacebook.com/drzanettainstagram.com/drzanetta

1st guest Lawrence Allen, author,/China expert discuss his podcast series, “The History You don’t Know!. 2nd guest Dr. Angela Stoehr, an OB/GYN, she discusses a new initiative called "Unlock Your X-Factor." She talks about the positive results of using non-opioids. Lastly, Denise Yardley, MD, Senior Investigator, Breast Cancer Research Program, Sarah Cannon Research Institute at Tennessee Oncology. She discusses the positive news emerging for advanced Breast Cancer patients.Let's Just Talk Radio Show is broadcast live at 2pm ET Thursdays on W4CY Radio (www.w4cy.com) part of Talk 4 Radio (www.talk4radio.com) on the Talk 4 Media Network (www.talk4media.com). This podcast is also available on Talk 4 Podcasting (www.talk4podcasting.com).

Up to 11% of new breast cancer cases are initially stage IV or metastatic. While there have been many advances in treatment, metastatic breast cancer remains incurable. Despite treatment advancements, metastatic breast cancer continues to take the lives of approximately 113 people in the US every day. Dr. Denise Yardley Senior Investigator, Breast Cancer Research Program, Sarah Cannon Research Institute at Tennessee Oncology has some positive news for advanced breast cancer patients.

Up to 11% of new breast cancer cases are initially stage IV or metastatic. While there have been many advances in treatment, metastatic breast cancer remains incurable. Despite treatment advancements, metastatic breast cancer continues to take the lives of approximately 113 people in the US every day. Dr. Denise Yardley Senior Investigator, Breast Cancer Research Program, Sarah Cannon Research Institute at Tennessee Oncology has some positive news for advanced breast cancer patients.

How does cancer grow? Why do some cancers react positively to treatment while others seem to resist? Understanding these relationships, the genetic events and cell-to-cell interactions that lead to cancer, not only can provide better understanding of how cancer develops, but also drive potential new targets for drug development. Understanding these relationships also essential to the incredible work being done by Dr. Ben Ho Park. Dr. Park was recently appointed as co-leader of the Breast Cancer Research Program, Associate Director for Translational Research, and Director of Precision Oncology at the Vanderbilt-Ingram Cancer Center in Nashville. He's been a BCRF investigator since 2008, and as you'll hear at the top, he also has a unique creative talent that surely won't directly lead to solving breast cancer, but it does to seem to make his lab an engaging and fun place to work. And who knows, perhaps in some way that creative culture is part of what inspires Dr. Park's creative research approaches.

Most women who die of breast cancer die from metastatic disease, the spread of tumor cells to different parts of the body. Metastasis often results following treatment failure, but it also can occur decades after what was thought to be successful treatment. Currently, no curative therapies exist for metastatic breast cancer.But today, the race to develop effective treatments for this disease is a key focus of some extraordinary research, much of it centering on cancer cells’ protein synthesis machinery and a protein called mTOR.What’s the status of this research – and what might some practical outcomes look like?I just had an incredibly thoughtful conversation with Dr. Robert Schneider. He’s the Associate Director of the NYU Cancer Institute, Director of Translational Cancer Research, and Co-director of the Breast Cancer Research Program at NYU School of Medicine. He’s also a BCRF Investigator since 2002.

Host: Barnett Mennen, MD Guest: Angela DeMichele, MD, MSCE Penn Medicine’s Breast Cancer Translational Center of Excellence (TCE), known as the 2-PREVENT TCE is led by Drs. Lewis Chodosh and Angela DeMichele. 2-PREVENT TCE aims to address one of the greatest challenges in breast cancer treatment: the high rate of relapse and late treatment effects among breast cancer survivors. Host Dr. Barry Mennen welcomes Dr. Angela DeMichele, the Alan and Jill Miller Endowed Chair in Breast Cancer Excellence, Professor of Medicine and Epidemiology, and Co-Leader of the Breast Cancer Research Program at the Abramson Cancer Center of the University of Pennsylvania School Of Medicine.

Host: Barnett Mennen, MD Guest: Angela DeMichele, MD, MSCE Penn Medicine’s Breast Cancer Translational Center of Excellence (TCE), known as the 2-PREVENT TCE is led by Drs. Lewis Chodosh and Angela DeMichele. 2-PREVENT TCE aims to address one of the greatest challenges in breast cancer treatment: the high rate of relapse and late treatment effects among breast cancer survivors. Host Dr. Barry Mennen welcomes Dr. Angela DeMichele, the Alan and Jill Miller Endowed Chair in Breast Cancer Excellence, Professor of Medicine and Epidemiology, and Co-Leader of the Breast Cancer Research Program at the Abramson Cancer Center of the University of Pennsylvania School Of Medicine.

Host: Barnett Mennen, MD Guest: Angela DeMichele, MD, MSCE Penn Medicine’s Breast Cancer Translational Center of Excellence (TCE), known as the 2-PREVENT TCE is led by Drs. Lewis Chodosh and Angela DeMichele. 2-PREVENT TCE aims to address one of the greatest challenges in breast cancer treatment: the high rate of relapse and late treatment effects among breast cancer survivors. Host Dr. Barry Mennen welcomes Dr. Angela DeMichele, the Alan and Jill Miller Endowed Chair in Breast Cancer Excellence, Professor of Medicine and Epidemiology, and Co-Leader of the Breast Cancer Research Program at the Abramson Cancer Center of the University of Pennsylvania School Of Medicine.

Host: Barnett Mennen, MD Guest: Angela DeMichele, MD, MSCE Penn Medicine’s Breast Cancer Translational Center of Excellence (TCE), known as the 2-PREVENT TCE is led by Drs. Lewis Chodosh and Angela DeMichele. 2-PREVENT TCE aims to address one of the greatest challenges in breast cancer treatment: the high rate of relapse and late treatment effects among breast cancer survivors. Host Dr. Barry Mennen welcomes Dr. Angela DeMichele, the Alan and Jill Miller Endowed Chair in Breast Cancer Excellence, Professor of Medicine and Epidemiology, and Co-Leader of the Breast Cancer Research Program at the Abramson Cancer Center of the University of Pennsylvania School Of Medicine.

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Interim Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Russell Swerdlow interview Dr. Charles Hall about his paper on how cognitive activities delay onset of memory decline. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about paraspinal myotonic discharges in acid maltase deficiency. The podcast concludes where Dr. Winn Cashion interviews Mr. Azhar Nizam for the Lesson of the Week segment about fixed effects and random effects. The participants had nothing to disclose except for Drs. Hall, Cashion and Mr. Nizam. Dr. Hall serves on the editorial board of The Open Neurology Journal; has received honoraria for serving on peer review panels for the National Cancer Institute, the Breast Cancer Research Program, Congressionally Directed Medical Research Programs, the U.S. Army Department of Defense, the National Institute of Child Health and Human Development, and the NIA; has received salary support from the NIH [P01 AG03949 (Core Leader), P01 AG027734 (Biostatistician), UL1-RR025750-01 (Biostatistician), K30 HL 04110 (Biostatistician), P30 CA13330-35 (Biostatistician), R01 AG017854 , National Alzheimer's Coordinating Center project 2008-01 (Biostatistician), P30 CA13330-33 (Biostatistician), the U. S. Department of Defense grant BC043301 (Biostatistician), the US National Institute of Occupational Safety and Health grant U1O-OH008242 (Biostatistician)]; receives research support from the Breast Cancer Research Foundation, the American Cancer Society, and the NIH [5R01HL070785-05 (Consultant) and 5R01AG022092-05 (Consultant)]; and is a member of the American Statistical Association Media Experts List. Dr. Cashion received academic sponsorship from the Emory University MD/PhD Program. Mr. Nizam received royalties from Duxbury/Cengage for applied regression analysis and other multivariable methods in 2007; is a consultant/instructor for SAS Institute (2001 to present); has received research support from the NIH completed support [0000655466 (Principal Investigator), 2000009946 (Principal Investigator), 8311-97649-5 (Co-investigator), 1U01GM070749 (Co-Investigator), NIH ongoing support [5 R01 MH066767-06 (Biostatistician), MUSC08-041 (Biostatistician), and 4 U10 EY013287-06 (Biostatistician).